Jacobson KA. Introduction to adenosine receptors as therapeutic targets. Handb Exp Pharmacol 2009; (193): 1-24.
Costanzi S, Ivanov AA, Tikhonova IG, Jacobson KA. Structure and function of G protein-coupled receptors studied using sequence analysis, molecular modeling, and receptor engineering: Adenosine receptors. Front Drug Design Disc 2007; 3: 63-79.
Cheng RK, Segala E, Robertson N, et al. Structures of human A1 and A2A adenosine receptors with xanthines reveal determinants of selectivity. Structure 2017; 25(8): 1275-1285.e4.
Sun B, Bachhawat P, Chu ML-H, et al. Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket. Proc Natl Acad Sci USA 2017; 114(8): 2066-71.
Chandrasekaran B, Abed SN, Al-Attraqchi O, Kuche K, Tekade RK. Computer-aided prediction of pharmacokinetic (ADMET) properties Dosage Form Design Parameters. Elsevier 2018; pp. 731-55.
Qing X, Lee XY, De Raeymaecker J, et al. Pharmacophore modeling: advances, limitations, and current utility in drug discovery. J Receptor Ligand Channel Res 2014; 7: 81-92.
Fan F, Hamadeh H, Warshaviak DT, Dunn R. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs. PLoS One 2019; 14(1)e0204378
Narke D, Siddiquee A, Patel M, et al. Limonene-induced activation of A2A adenosine receptors reduces airway inflammation and reactivity in a mouse model of asthma. FASEB J 2017; 31(1): 820.
Jones T, Murray R. Current research in and development of treatments for Parkinson’s disease. J Pharm 2011; 287: 293.
Yamada K, Kobayashi M, Kanda T. Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol 2014; 119: 373-93.
Hart E, Conoscenti M, Minor T. Animal models of depression: A focus on adenosine signaling at A2A receptors. Ann Depress Anxiety 2014; 1: 1285-92.
Dziubina A, Zygmunt M, Filipek B, et al. The role of adenosine A2A receptors in antidepressant activity in experimental animal model of depression. Int Med Rev 2017; 27(109): 228-36.
Gourdin N, Bossennec M, Rodriguez C, et al. Autocrine Adenosine regulates tumor polyfunctional CD73+ CD4+ effector T cells devoid of immune checkpoints. Cancer Res 2018; 78(13): 3604-18.
Chiappori A, Williams CC, Creelan BC, Tanvetyanon T, Gray JE, Haura EB, et al. Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC. J Clin Oncol 2018; 36(15): 9089-9.